Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tavargenix GmbH manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This specific action is located in 1 distinct art unit. A practitioner managing this portfolio interacts with 1 distinct examiner to address the outstanding issues.
The busiest examiner for this entity is TATGE, LEXUS MARC, who is currently responsible for 1 busiest examiner pending office action. This figure matches the total number of 1 pending office action for the entire portfolio. This means the prosecution workload is entirely handled by this examiner. Such a structure allows for a direct and consistent dialogue between the applicant and the USPTO.
Because the work is limited to 1 distinct art unit, the technical arguments required for these filings are specific to that unit's standards. The presence of 1 distinct examiner means that the legal strategy does not need to account for different examiner behaviors across the applications. The data shows a prosecution environment where all active matters are funneled through TATGE, LEXUS MARC, which simplifies the administrative oversight of the Tavargenix GmbH company patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554636 | TKTL1 INHIBITORS FOR ANTIVIRAL THERAPY | TATGE, LEXUS MARC | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554636 | TKTL1 INHIBITORS FOR ANTIVIRAL THERAPY | TATGE, LEXUS MARC | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Oct 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial